BioNexus Gene Lab Corp.
BGLCNASDAQMaterialsSpecialty Chemicals
As of Oct 26, 2026 close
- Market cap
- $2.80M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $1.07$5.89
- Volume (live)
- -
- Avg. volume (3M)
- 7.25K
BioNexus Gene Lab (BGLC) Stock Price & Financial Analysis
BioNexus Gene Lab Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $1.15 - $1.16 |
|---|---|
| 52-Week High | $5.89 |
| 52-Week Low | $1.07 |
| Open | $1.15 |
| Volume (last close) | 1.24K |
| Average Volume (3M) | 7.25K |
| Revenue (TTM) | 3.13M |
|---|---|
| Net Income (TTM) | -2.58M |
| Free Cash Flow (TTM) | -853.60K |
| EPS (TTM) | −$1.21 |
| Profit Margin | -82.36% |
| Operating Margin | -87.18% |
| Return on Equity (ROE) | -33.11% |
| Debt to Equity | 0.03 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 2.80M |
|---|---|
| Shares Outstanding | 2.42M |
| Price to Sales (P/S) | 0.90 |
| Price to Book (P/B) | 0.36 |
| EV/EBITDA | -0.76 |
| 50-Day MA | $1.43 |
|---|---|
| 200-Day MA | $2.07 |
| 1-Year Change | −77.07% |
Source: Market prices and company fundamentals. Data as of Oct 26, 2026. Data sources and methodology
BioNexus Gene Lab at a Glance
As of the Oct 26, 2026 close, BioNexus Gene Lab (BGLC) has a market capitalization of $2.80M. The stock trades at 0.9× sales. Over the trailing twelve months it lost $2.58M on revenue of $3.13M and burned $853.60K of free cash flow. Revenue fell 67.3% year over year.
As of its latest reported balance sheet, it holds $1.23M in cash and securities against $198.59K of debt, a net cash position of $1.03M.
BioNexus Gene Lab does not currently pay a dividend.
The share price is down 77.1% over the past year. At $1.16 (the Oct 26, 2026 close) it sits near the bottom of its 52-week range of $1.07 to $5.89, below its 200-day moving average of $2.07.
Frequently Asked Questions About BioNexus Gene Lab
What is the current stock price for BGLC?
As of the Oct 26, 2026 close, BGLC stock trades at $1.16. The 52-week range is $1.07–$5.89, with a day range of $1.15–$1.16.
What is the P/E ratio for BGLC?
The P/E ratio (Price-to-Earnings) for BGLC is shown in the Key Statistics section. This valuation metric helps compare BioNexus Gene Lab Corp. to industry peers.
Does BGLC pay dividends?
BioNexus Gene Lab does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for BGLC?
Analyst ratings and recommendations for BGLC are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.
What is the market cap of BGLC?
As of the Oct 26, 2026 close, BioNexus Gene Lab's market capitalization is $2.8M, classifying it as a micro-cap company. BioNexus Gene Lab operates in the Materials sector within the Specialty Chemicals industry.